This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Regeneron Pharmaceuticals (REGN)
by Ethan Feller
The Biotechnology company enjoys a litany of bullish catalysts on the horizon
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $106.35, denoting a -0.76% change from the preceding trading day.
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
by Zacks Equity Research
Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.
Best Growth Stocks to Buy for January 16th
by Zacks Equity Research
NVO, AIZ and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 16, 2024.
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.
Centene (CNC) Sells Circle Health to Boost Managed Care Business
by Zacks Equity Research
Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.
Here is Why Growth Investors Should Buy Novo Nordisk (NVO) Now
by Zacks Equity Research
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
by Zacks Equity Research
Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
Novo Nordisk (NVO) Is Up 2.45% in One Week: What You Should Know
by Zacks Equity Research
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.
UnitedHealth Group (UNH) Q4 Earnings Beat on Membership Growth
by Zacks Equity Research
UnitedHealth Group's (UNH) Q4 results benefit on the back of double-digit revenue growth in its UnitedHealthcare and Optum segments. Management maintains its 2024 adjusted EPS target within $27.50-$28.00.
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
by Zacks Equity Research
Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
Should You Invest in Novo Nordisk (NVO) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts
by Kinjel Shah
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Bullish Continuation in '24? 3 Market Areas to Watch
by Andrew Rocco
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $106.95, indicating a +0.52% shift from the previous trading day.
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
by Zacks Equity Research
Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
by Zacks Equity Research
Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates
by Zacks Equity Research
Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.